GHRP-2 Acetate is the acetate salt form of growth hormone-releasing peptide-2, a synthetic hexapeptide also known by its international nonproprietary name, pralmorelin. It acts as a full agonist at the growth hormone secretagogue receptor, GHS-R1a, the same receptor bound by the endogenous hormone ghrelin, and it is studied for its stimulatory effect on pituitary growth hormone release. Laboratory research on GHRP-2 spans pituitary cell signalling, the somatotropic axis, and comparative work against other growth hormone secretagogues. This article reviews the peptide's structure, mechanism, the published preclinical and clinical literature, its research applications and the handling requirements relevant to a laboratory setting.
What is GHRP-2 Acetate?
GHRP-2 is a synthetic hexapeptide with the sequence D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH₂, meaning it is built from six amino acid residues, several in the D-configuration, with a C-terminal amide. Its free-base molecular weight is approximately 818 g/mol, and it carries the CAS registry number 158861-67-7. Commercial research material is typically supplied as the acetate salt, in which acetic acid is associated with the peptide during lyophilisation; this affects the measured mass of the salt form and the counter-ion content reported on a certificate of analysis, without altering the peptide's own sequence or receptor activity.
GHRP-2 was developed by Cyril Bowers and colleagues at Tulane University as part of a research programme into synthetic peptides that release growth hormone. The earlier compound in that series, GHRP-6, was reported in 1984 as a hexapeptide that specifically released growth hormone in vitro and in vivo without significantly affecting other pituitary hormones. GHRP-2 was subsequently identified as a second-generation analogue, incorporating unnatural amino acids such as D-2-naphthylalanine, with the aim of improving potency and receptor selectivity relative to GHRP-6. In Japan, GHRP-2 is marketed as a diagnostic agent, under the name pralmorelin, for assessing growth hormone secretory capacity; that use falls outside the scope of this article, which concerns laboratory research material only.
Mechanism of action
GHRP-2 acts on the growth hormone secretagogue receptor 1a (GHS-R1a), a seven-transmembrane G protein-coupled receptor expressed on somatotroph cells of the anterior pituitary and on neurons in the hypothalamic arcuate nucleus. GHS-R1a is the receptor later identified, in 1999, as the target of the endogenous hormone ghrelin, which places GHRP-2 among a class of compounds now understood as ghrelin receptor agonists rather than analogues of growth hormone-releasing hormone (GHRH).
Receptor engagement activates Gq/11-coupled phospholipase C, generating inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from intracellular stores, while DAG activates protein kinase C. The resulting rise in intracellular calcium is reported to drive exocytosis of growth hormone-containing secretory vesicles from somatotrophs. This pathway is distinct from that of GHRH, which signals mainly through a Gs-coupled receptor and cyclic AMP.
Because the two pathways are mechanistically separate, several studies have examined co-administration of GHRP-2 and GHRH in cell culture, and have reported that the combined growth hormone response exceeds that produced by either compound alone. Somatostatin, the endogenous inhibitor of growth hormone release, has been reported to suppress the GHRP-2 response in pituitary cell culture, consistent with GHRP-2 acting on the same physiological cascade that somatostatin restrains, rather than bypassing it. Voltage-dependent calcium channel blockade has also been shown to reduce GHRP-2-stimulated hormone release in vitro, supporting the calcium-dependent step described above.
What the research shows
The mechanistic basis for calcium- and protein kinase C-dependent signalling was examined directly in bovine anterior pituitary cell culture. Researchers reported in the Journal of Animal Science in 1997 that GHRP-2, across a range of concentrations, increased growth hormone secretion, and that this response was reduced by a growth hormone-releasing factor receptor antagonist, by a calcium channel blocker, and was further stimulated by a protein kinase C activator and a cyclic AMP-elevating agent (Bowers et al., 1997, PubMed). The authors concluded that GHRP-2 stimulates growth hormone secretion through calcium influx and protein kinase C- and cyclic AMP-linked pathways, and that it may partly involve the growth hormone-releasing factor receptor.
In humans, a 2005 study published in the Journal of Clinical Endocrinology & Metabolism examined whether GHRP-2, given acutely to healthy men, affected food intake, drawing on its shared receptor with ghrelin. The investigators reported that intravenous GHRP-2 administration increased subsequent food intake relative to placebo, providing evidence that ghrelin-receptor activation influences appetite in humans as well as in the animal studies that had previously been reported (Laferrère et al., 2005, PMC).
Comparative dose-response work has also been carried out in production-animal models. Studies in calves and goats have examined intravenous GHRP-2 across a range of microgram-per-kilogram doses and reported dose-dependent increases in circulating growth hormone, with response profiles differing from those produced by growth hormone-releasing factor at equivalent doses. These studies illustrate that the peptide's activity has been confirmed across several species, consistent with the lack of species specificity reported for the GHRP class more broadly.
Diagnostic evaluation studies conducted in Japan, using GHRP-2 as a growth hormone provocative test, have compared its sensitivity and specificity against the insulin tolerance test in patients with suspected growth hormone deficiency. These studies sit within a clinical and diagnostic context distinct from the in-vitro and preclinical research summarised above, and are noted here for completeness rather than as a basis for any claim about the research-grade material discussed in this article.
Research applications
In the laboratory, GHRP-2 is used mainly as a pharmacological tool for probing GHS-R1a signalling. Pituitary cell culture models, both primary cells and immortalised lines, are treated with GHRP-2 alone or alongside GHRH to dissect the calcium, protein kinase C and cyclic AMP components of the growth hormone secretory pathway described above. Receptor antagonists and pathway inhibitors are commonly included as controls, as in the bovine pituitary study cited above.
Comparative pharmacology is a second application. Because GHRP-2 belongs to a family that also includes GHRP-6, GHRP-1 and hexarelin, researchers use it as a reference compound when characterising newer growth hormone secretagogues, examining relative potency, selectivity for growth hormone release over other pituitary hormones such as cortisol and prolactin, and duration of receptor activation.
GHRP-2 is also used in studies of the ghrelin receptor system more broadly, including appetite and feeding behaviour research of the kind reported in the human study above, and in comparative endocrinology work examining growth hormone secretagogue responses across species, from rodents to production animals such as calves and goats.
Purity, storage and handling
Because degradation accelerates once reconstituted, batch-level HPLC verification matters more here than with more stable peptides. UK laboratories sourcingGHRP-2 Acetate should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and those askingWhere to buy peptides Ireland should look for the same evidence before selecting a source.
Reversed-phase HPLC separates the target hexapeptide from truncated or deletion sequences and residual synthesis by-products, and research-grade material is commonly specified at 98% purity or above. Because GHRP-2 is supplied as an acetate salt, mass spectrometry alongside HPLC helps confirm both the peptide's identity, against its expected free-base mass of roughly 818 daltons, and the counter-ion content that a CoA should separately report. A batch-specific certificate of analysis, rather than a generic product datasheet, is what links a physical vial to those results and allows unexpected data to be traced back to a defined lot.
Lyophilised GHRP-2 acetate should be kept sealed at -20°C for long-term storage, protected from moisture and light, and brought to room temperature before opening so that condensation does not enter the vial. Once reconstituted in sterile water or an appropriate buffer, the peptide should be divided into single-use aliquots, held at 2–8°C only for short working periods, and otherwise kept frozen, since repeated freeze–thaw cycles promote degradation. The tryptophan residue in the sequence is particularly susceptible to photo-oxidation, so amber vials or foil-wrapped storage are sensible precautions. Published reconstituted-stability data specific to GHRP-2 are limited, so laboratories should validate their own working window, for example by re-running HPLC on aliquots at defined time points.
Frequently asked questionsWhat is GHRP-2 Acetate used for in research?
It is used as a tool compound for studying growth hormone secretagogue receptor (GHS-R1a) signalling, pituitary calcium and protein kinase C pathways, and comparative pharmacology against related peptides such as GHRP-6 and hexarelin. It is also used in animal and cell-based ghrelin-receptor research. It is not approved as a medicine, and nothing here concerns use in humans.
What is the difference between GHRP-2 and GHRP-6?
Both are synthetic hexapeptide agonists of the GHS-R1a receptor developed in the same Bowers research programme, but they differ in sequence and in reported selectivity. Published comparisons describe GHRP-2 as producing a growth hormone response with comparatively less accompanying effect on cortisol and prolactin secretion than GHRP-6 in the studies that have examined both peptides.
How should GHRP-2 Acetate be stored once reconstituted?
Reconstituted material should be aliquoted for single use, kept refrigerated only briefly and otherwise frozen, protected from light, and not subjected to repeated freeze–thaw cycles. Because specific published stability data are limited, laboratories should confirm their own storage window empirically, for example with HPLC comparisons of fresh and aged aliquots.
Is GHRP-2 the same as pralmorelin?
Yes. Pralmorelin is the international nonproprietary name for the GHRP-2 sequence, and the two terms refer to the same peptide. Pralmorelin is registered as a diagnostic agent in Japan, whereas laboratory-grade GHRP-2 acetate sold for research is a reagent for in-vitro and preclinical use and is not equivalent to a licensed diagnostic or therapeutic product.
The GHRP-2 Acetate discussed in this article is supplied for in-vitro laboratory research only. It is not intended for human or veterinary use, and nothing in this article should be read as guidance on administration to people or animals.
Comments (0)